0001143313-13-000104.txt : 20130830
0001143313-13-000104.hdr.sgml : 20130830
20130830112240
ACCESSION NUMBER: 0001143313-13-000104
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20130830
DATE AS OF CHANGE: 20130830
EFFECTIVENESS DATE: 20130830
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: PROLOR Biotech, Inc.
CENTRAL INDEX KEY: 0001268659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34676
FILM NUMBER: 131071444
BUSINESS ADDRESS:
STREET 1: 3 SAPIR STREET
STREET 2: WEIZMANN SCIENCE PARK
CITY: NES-ZIONA
STATE: L3
ZIP: 74140
BUSINESS PHONE: (866) 644-7811
MAIL ADDRESS:
STREET 1: 3 SAPIR STREET
STREET 2: WEIZMANN SCIENCE PARK
CITY: NES-ZIONA
STATE: L3
ZIP: 74140
FORMER COMPANY:
FORMER CONFORMED NAME: Modigene Inc.
DATE OF NAME CHANGE: 20070227
FORMER COMPANY:
FORMER CONFORMED NAME: LDG INC
DATE OF NAME CHANGE: 20031030
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE MKT LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 20 BROAD STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5024
MAIL ADDRESS:
STREET 1: 20 BROAD STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN STOCK EXCHANGE LLC
DATE OF NAME CHANGE: 20010620
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE MKT LLC
0001268659
PROLOR Biotech, Inc.
001-34676
3 SAPIR STREET
WEIZMANN SCIENCE PARK
NES-ZIONA
L3
ISRAEL
74140
(866) 644-7811
Common Stock
17 CFR 240.12d2-2(a)(3)
Paras Madho
Director
2013-08-30
EX-99.25
2
pbth.txt
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED
SECURITIES
The null hereby notifies the SEC of its intention to remove the entire
class of the stated securities from listing and registration on the
Exchange at the opening of business on September 10, 2013, pursuant
to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on August 29, 2013 the
instruments representing the securities comprising the entire class
of this security came to evidence, by operation of law or otherwise,
other securities in substitution therefore and represent no other right
except, if such be the fact, the right to receive an immediate cash
payment.
The merger between PROLOR Biotech, Inc. and OPKO Health, Inc. became
effective on August 29, 2013. Each share of Common Stock of PROLOR
Biotech, Inc. was converted into 0.9951 of a share of Common Stock
of OPKO Health, Inc.
The Exchange also notifies the Securities and Exchange Commission that
as a result of the above indicated conditions this security was
suspended from trading on August 30, 2013.